AVTE — Aerovate Therapeutics Share Price
Last Trade - 00:00- $274.66m
- $266.02m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The Company's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101's anti-proliferative mechanism is distinguished from vasodilatory therapies and poised to make a meaningful difference in the lives of PAH patients. The Company has completed a Phase I trial in the United States of AV-101 in 82 healthy adults. In its Phase I trial, there were no adverse events associated with AV-101. It anticipates initiating a double-blinded, placebo-controlled, randomized Phase II b/III trial of AV-101.
Directors
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- January 1st, 1970
- Public Since
- January 1st, 1970
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 21,575,930
- Address
- 200 Berkeley Street, Floor 18, BOSTON, 02116
- Web
- https://www.aerovatetx.com/
- Phone
- +1 6174432400
- Auditors
- KPMG LLP
Latest News for AVTE
Similar to AVTE
AC IMMUNE SA ORD
NASDAQ Global Market
ADAMAS PHARMACEUTICALS ORD
NASDAQ Global Market
ADICET BIO ORD
NASDAQ Global Market
AMICUS THERAPEUTICS ORD
NASDAQ Global Market
ARCTURUS THERAPEUTICS HOLDINGS ORD
NASDAQ Global Market
FAQ
As of Today at 19:56 UTC, shares in Aerovate Therapeutics are trading at $12.73. This share price information is delayed by 15 minutes.
Shares in Aerovate Therapeutics last closed at $12.73 and the price had moved by over the past 365 days. In terms of relative price strength the Aerovate Therapeutics share price has matched the S&P500 Index by over the past year.
The overall consensus recommendation for Aerovate Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Aerovate Therapeutics does not currently pay a dividend.
Aerovate Therapeutics does not currently pay a dividend.
Aerovate Therapeutics does not currently pay a dividend.
To buy shares in Aerovate Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $12.73, shares in Aerovate Therapeutics had a market capitalisation of $274.66m.
Here are the trading details for Aerovate Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: AVTE
Based on an overall assessment of its quality, value and momentum Aerovate Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Aerovate Therapeutics is $24.67. That is 93.79% above the last closing price of $12.73.
Analysts covering Aerovate Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.89 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aerovate Therapeutics. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $12.73, shares in Aerovate Therapeutics were trading -13.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Aerovate Therapeutics.
We do not have data on Aerovate Therapeutics' directors
We do not have data on Aerovate Therapeutics' shareholders